AVITA MEDICAL WKN: A0Q40S ISIN: AU000000AVH4 Kürzel: AVMXF Forum: Aktien Thema: Hauptdiskussion

AVITA Medical GAAP EPS of -$0.41 misses by $0.10, revenue of $11.75M beats by $0.18M https://seekingalpha.com/news/4001261-avita-medical-gaap-eps-of-0_41-misses-0_10-revenue-of-11_75m-beats-0_18m • AVITA Medical press release (NASDAQ:RCEL): Q2 GAAP EPS of -$0.41 misses by $0.10. • Revenue of $11.75M (+40.9% Y/Y) beats by $0.18M. • Financial Guidance • Commercial revenue for the third quarter 2023 is expected to be in the range of $13 to $14 million • Raising commercial revenue for the full year 2023 from $49 to $51 million to an expected range of $51 to $53 million • Gross margin for the full year 2023 expected to be in the range of 83% to 85%

AVITA Medical Reports Second Quarter Financial Results https://www.globenewswire.com/news-release/2023/08/10/2723105/0/en/AVITA-Medical-Reports-Second-Quarter-Financial-Results.html

https://beststocks.com/avita-medical-receives-positive-outlook-and-i/

AVITA's Balancing Act: RECELL System's Promise Amid Market Uncertainties https://seekingalpha.com/article/4618423-avitas-balancing-act-recell-systems-promise-amid-market-uncertainties

AVITA Medical Submits FDA PMA Supplement for RECELL GO https://finance.yahoo.com/news/avita-medical-submits-fda-pma-222100572.html

Skin Grafts Disruption: Avita Medical's Regenerative Medicine System Poised to Disrupt Traditional Skin Grafts, Says Analyst https://markets.businessinsider.com/news/stocks/skin-grafts-disruption-avita-medical-s-regenerative-medicine-system-poised-to-disrupt-traditional-skin-grafts-says-analyst-1032413234 Cantor Fitzgerald has initiated coverage on Avita Medical Inc (NASDAQ:RCEL) at an Overweight rating and a price target of $23.  The analyst notes that the company's RECELL system will disrupt traditional split-thickness skin grafts, requiring 97.5% less donor skin when used alone in second-degree burns and 32.0% less donor skin when used with autograft for third-degree burns. It requires 56% and 60% fewer autograft procedures for pediatric and adult patients with >60% TBSA (total body surface area), respectively, a shorter length of hospital stay, and reduced scarring and pain. ...

AVITA Medical Rejoins the Russell 3000 Index https://www.globenewswire.com/news-release/2023/06/26/2694404/0/en/AVITA-Medical-Rejoins-the-Russell-3000-Index.html

AVITA scores US FDA approval for vitiligo treatment https://www.businessnewsaustralia.com/articles/avita-scores-us-fda-approval-for-vitiligo-treatment.html

AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients https://www.globenewswire.com/news-release/2023/06/16/2689906/0/en/AVITA-Medical-Announces-FDA-Approval-of-RECELL-for-Skin-Repigmentation-in-Vitiligo-Patients.html

Da fehlt aber noch die Zulassung für vitiligo oder?

👍 hört sich schon mal gut an

AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects https://www.businessupturn.com/brand-post/avita-medical-announces-fda-approval-of-recell-for-treatment-of-full-thickness-skin-defects/

AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-first-quarter-financial-results-and

Wann rechnet ihr mit den Zulassungen die im dritten Quartal 23 eingeführt werden sollen?

AVITA Medical Announces Update to Automation Device https://www.globenewswire.com/news-release/2023/04/13/2646762/0/en/AVITA-Medical-Announces-Update-to-Automation-Device.html

Kurseinbruch auf SVB Pleite zurückzuführen oder gab es andere news?